Morphine Dosing for Cough Suppression

Initial Dosing Strategy

The American College of Chest Physicians recommends starting with oral morphine 5 mg as a single-dose trial, and if effective, transitioning to 5-10 mg slow-release morphine twice daily for sustained control 1
For patients already receiving morphine for other indications, such as pain management, the guideline suggests increasing their current dose by 20% to achieve antitussive effect, though this recommendation is based on clinical experience rather than formal evidence 1

In patients with lung cancer experiencing nonspecific cough in the palliative stage, a bedtime dose of morphine is particularly useful to suppress nocturnal cough and promote undisturbed sleep 1

The evidence supports a hierarchical approach, starting with first-line demulcents (simple linctus, glycerol-based preparations) due to low cost and minimal side effects, as recommended by the American College of Chest Physicians 1, 2
Second-line treatment considers other opioid derivatives, such as codeine 30-60 mg four times daily, pholcodine 10 mL four times daily, or hydrocodone 5 mg twice daily, before morphine 1, 3
Third-line treatment involves morphine at the specified doses when other opioids prove inadequate, as recommended by the American College of Chest Physicians 1, 2
Fourth-line treatment includes peripherally-acting antitussives, such as levodropropizine 75 mg three times daily or moguisteine 100-200 mg three times daily, for opioid-resistant cough 1
Last resort treatment involves nebulized local anesthetics, such as lidocaine 5 mL of 0.2% three times daily, after careful aspiration risk assessment, as recommended by the American College of Chest Physicians and Praxis Medical Insights 1, 2

Morphine carries a significant side effect burden, including drowsiness, nausea, constipation, and potential for physical dependence, which is why it should be reserved for cases where simpler measures have failed, as noted by the American College of Chest Physicians and Praxis Medical Insights 1, 2
The evidence quality supporting morphine for cough is generally low methodologically, though clinical experience supports its use in refractory cases, as reported by the American College of Chest Physicians and Praxis Medical Insights 1, 2
It is essential to avoid using morphine to mask symptoms without addressing underlying treatable causes of cough, such as asthma, gastroesophageal reflux, or postnasal drip, as recommended by Praxis Medical Insights 2
Codeine and pholcodine have no greater efficacy than dextromethorphan but carry worse side effect profiles, making morphine a more rational choice when escalating beyond non-opioid options, according to the Thorax journal 4